Compare HCKT & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCKT | LYEL |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.1M | 320.1M |
| IPO Year | 1998 | 2021 |
| Metric | HCKT | LYEL |
|---|---|---|
| Price | $11.13 | $14.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $17.00 | ★ $30.60 |
| AVG Volume (30 Days) | ★ 244.8K | 135.6K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $285,862,000.00 | $36,000.00 |
| Revenue This Year | $2.55 | N/A |
| Revenue Next Year | $5.07 | $8,712.13 |
| P/E Ratio | $32.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.16 | $11.47 |
| 52 Week High | $21.33 | $45.00 |
| Indicator | HCKT | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 55.53 | 55.43 |
| Support Level | $9.90 | $11.87 |
| Resistance Level | $11.64 | $15.63 |
| Average True Range (ATR) | 0.34 | 0.93 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 77.17 | 46.54 |
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.